Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Potential Homeruns--Credible, and Reporting -- Ignore unavailable to you. Want to Upgrade?

To: Ted M who wrote (497)	2/16/2010 1:17:40 AM
From: caly	Read Replies (1) \| Respond to of 1056

marketwatch.com For the full year 2010, Senomyx expects: -- Total revenues of $20 million to $24 million -- Total expenses of $42 million to $44 million, of which $5 million to $6 million is non-cash, stock-based compensation expense -- Net loss of $18 million to $21 million -- Basic and diluted net loss of $0.57 to $0.67 per share -- Net cash used in operating activities between $14 million and $16 million As far as GNVC goes, I read an article in a local business journal about them not long ago and remembered them from years ago as supposedly having promising things in the pipeline. I did a little more reading, and there's a lot of very optimistic people people out there, so I decided to roll the dice...literally, because all these pharmas seem to be total crapshoots. I've done well with some just on a hunch, though, and it keeps me coming back.